1. What This Condition Is
Soft-tissue sarcomas are a diverse group of malignant tumors that arise from the connective tissues of the body — muscle, fat, tendons, blood vessels, lymph vessels, nerves, and joint tissue. They can occur anywhere in the body but most commonly develop in the extremities (arms and legs), trunk, and retroperitoneum. Because soft-tissue sarcomas can develop in so many different tissue types, there are more than 50 recognized subtypes, including liposarcoma (fatty tissue), leiomyosarcoma (smooth muscle), fibrosarcoma (fibrous tissue), rhabdomyosarcoma (skeletal muscle), synovial sarcoma (joint tissue), malignant peripheral nerve sheath tumor (nerve tissue), and others.
Soft-tissue sarcomas are among the original Agent Orange presumptive conditions listed under 38 CFR 3.309(e). The regulatory listing covers soft-tissue sarcomas as a category, which means that any of the recognized histological subtypes qualifies for the presumptive. Veterans exposed to tactical herbicides during qualifying service who develop soft-tissue sarcoma of any type do not need to prove a direct medical connection between their exposure and diagnosis.
The presumptive covers veterans who served in Vietnam, the Korean Demilitarized Zone between April 1, 1968 and August 31, 1971, Air Force personnel who handled or maintained herbicide-sprayed aircraft, veterans at specific stateside testing locations, and Blue Water Navy veterans under the 2019 act.
Soft-tissue sarcomas are relatively rare malignancies and are often initially misdiagnosed as benign masses or cysts. Veterans with any unexplained soft-tissue mass, particularly in the extremities, should undergo MRI evaluation and, if needed, biopsy before accepting a benign diagnosis. A delayed or missed diagnosis of soft-tissue sarcoma can significantly affect treatment outcomes.
2. VA Rating Criteria
Soft-tissue sarcomas are rated under 38 CFR § 4.114, Diagnostic Code 7820 (Soft-tissue malignant neoplasms, primary) or under the applicable code for the anatomic location of the tumor. The specific code used may vary depending on where in the body the sarcoma is located and which tissue system is most affected.
Active disease or treatment: A 100% rating applies during any period of active soft-tissue sarcoma or during any treatment — including surgery, chemotherapy, radiation therapy, or targeted therapy.
Post-treatment: Following completion of treatment, the 100% rating continues for a minimum of six months. After that period, the VA schedules a rating examination to assess residual disability.
Residual ratings: After treatment, the veteran is rated based on residual functional impairment from surgery, radiation, chemotherapy, or disease recurrence. Common residuals include:
- Limb function loss from surgical resection (wide local excision, limb-sparing surgery, or amputation): rated under the musculoskeletal or amputation codes based on the extent of functional loss
- Peripheral neuropathy from chemotherapy
- Lymphedema from lymph node dissection or radiation to regional lymphatics
- Local radiation effects producing fibrosis, skin changes, or restricted motion in adjacent joints
- Pulmonary metastasis and residual pulmonary dysfunction
If a limb-sparing resection was performed, the residual rating depends on how much muscle, nerve, or bone was removed and the resulting functional limitation in the affected extremity. If amputation was required, the applicable amputation diagnostic codes under 38 CFR 4.71a apply.
3. What to Expect at Your C&P Exam
For active disease, the examiner confirms the diagnosis, stage, and treatment status. The 100% rating is applied during active disease without further functional assessment.
For a residual exam after treatment, the examiner will evaluate functional impairment in the affected anatomic region. Be prepared to describe:
- The location and extent of surgical resection, and what functional capacity was lost
- Range of motion in any joints affected by surgical resection, radiation, or fibrosis
- Lymphedema if regional lymphatics were removed or irradiated
- Neuropathy symptoms if chemotherapy was part of the treatment regimen
- Any evidence of recurrence, metastasis, or secondary complications
Bring all surgical operative reports, pathology reports, and post-operative functional assessments. If physical therapy records document your range of motion and strength post-surgery, those support the residual rating.
For extremity sarcomas, the examiner must assess whether residual functional loss is captured by the amputation schedule (if amputation occurred) or by the limitation-of-motion and muscle injury codes (if limb-sparing surgery was performed).
4. Evidence You Need to Win
Diagnosis: Pathology report confirming soft-tissue sarcoma with histological subtype, grade, and stage. MRI or CT imaging documenting tumor location and extent. All oncology treatment records including surgical operative reports, chemotherapy summaries, and radiation field documentation.
Service Record Evidence (Presumptive Claims): Documentation of qualifying service in Vietnam, the Korean DMZ, or other covered herbicide-exposure locations. For Blue Water Navy veterans, ship logs confirming vessel assignment.
No Nexus Letter Required for Presumptive Claims: If the Agent Orange presumptive applies, file with diagnosis and qualifying service documented. No physician nexus is required.
Nexus Letter (Non-Presumptive Direct Claims): Veterans whose sarcoma claim rests on a different service-connected cause need an oncologist's or surgical oncologist's nexus opinion.
DBQ Form: The appropriate malignant neoplasm DBQ for the anatomic location. For extremity sarcomas, the musculoskeletal DBQ for the affected extremity may also be required to document residual functional loss.
Residual Functional Documentation: Post-surgical range-of-motion records from orthopedic surgeons or physical therapists. Lymphedema measurements if lymphatics were removed or irradiated. Pulmonary function testing if pulmonary metastases affected respiratory function.
Personal Statement: Describe the functional impact of surgery, radiation, and chemotherapy. For extremity sarcomas, describe what you can no longer do with the affected limb: lifting, carrying, gripping, walking, or climbing stairs.
Buddy Statements (VA Form 21-10210): Observers who can describe your functional limitations post-surgery or during treatment provide lay corroboration.
5. Secondary Conditions to Consider
Lymphedema: Removal or irradiation of regional lymph nodes produces chronic lymphedema in the affected extremity. Secondary lymphedema is separately ratable based on the degree of swelling and functional limitation.
Peripheral Neuropathy: Chemotherapy agents used for soft-tissue sarcomas produce peripheral neuropathy. Secondary neuropathy from treatment of service-connected sarcoma is ratable.
Joint and Musculoskeletal Residuals: Wide local excision and radiation to adjacent tissues can produce fibrosis that restricts joint motion. Secondary limitation of motion in the adjacent joints is ratable under the applicable musculoskeletal codes.
Pulmonary Metastasis Residuals: Soft-tissue sarcomas commonly metastasize to the lungs. Pulmonary metastases and their treatment can produce residual pulmonary impairment ratable under the respiratory schedule.
Depression and Anxiety: A sarcoma diagnosis — a relatively rare and often feared malignancy — produces significant psychological burden. Secondary mental health claims are ratable under 38 CFR 3.310.
Wound Complications and Chronic Pain: Complex surgical wounds from sarcoma resection can produce chronic wound complications, scarring, and pain syndromes that may be separately ratable.
6. Common Mistakes That Kill Claims
Not filing because the sarcoma seems too rare to be service-connected. The Agent Orange presumptive for soft-tissue sarcomas covers the entire category of histological types. Rarity is not a disqualifying factor. If you have qualifying service and a soft-tissue sarcoma diagnosis, you have the presumptive.
Not knowing soft-tissue sarcoma is a listed Agent Orange presumptive. Many veterans and even some VSOs are unfamiliar with the full list of 14 original Agent Orange presumptives. Soft-tissue sarcoma has been on the list since the inception of the presumptive scheme. File immediately on diagnosis if you have qualifying service.
Failing to claim limb function loss as a residual. Veterans who underwent limb-sparing surgery often do not realize that the resulting limitation of motion, muscle loss, or weakness is ratable as a residual condition. Obtain post-surgical range-of-motion assessments from your orthopedic surgeon or physical therapist and file for residual musculoskeletal impairment.
Missing lymphedema as a secondary claim. Soft-tissue sarcoma treatment frequently involves lymph node dissection or radiation to regional lymphatics, producing chronic lymphedema. File for secondary lymphedema with documentation of the swelling and its functional impact.
Not pursuing Blue Water Navy coverage. Veterans previously denied on the basis of offshore service should file a Supplemental Claim under the Blue Water Navy Vietnam Veterans Act of 2019.
7. FWD Assist Resources
The following FWD Assist HQ books are directly relevant to a soft-tissue sarcoma claim:
- Agent Orange: The Complete Vietnam Veterans Claims Guide — comprehensive coverage of the presumptive list including soft-tissue sarcomas, qualifying service locations, Blue Water Navy provisions, and how to file
- C&P Exam Prep Guide — covers cancer residual exams and how to document surgical and treatment-related residuals for the rating evaluation
- Secondary Conditions Guide — covers lymphedema, neuropathy, musculoskeletal residuals, and mental health secondary chains from service-connected sarcoma
- The PACT Act Playbook — covers the PACT Act expansion for post-9/11 veterans and additional exposure locations that may support claims outside the Agent Orange framework
All titles are available at fwdassisthq.com.
8. Get Help Without a Claim Shark
Free, accredited help is available through Veterans Service Organizations including the DAV, VFW, American Legion, and AMVETS. County Veterans Service Officers (CVSOs) file and manage claims at no cost.
Charging upfront fees to assist with a VA claim is illegal under 38 U.S.C. § 5905. VA-accredited attorneys and claims agents may charge fees only after an initial VA decision, capped at 20% of past-due benefits under 38 U.S.C. § 5904. No legitimate representative asks for money before your first decision.
Verify accreditation at va.gov/ogc/accreditation.asp.